ligands acting on targets

(±)-Blebbistatin.

(±)-Blebbistatin.

(±)-Butaclamol hydrochloride.

(±)-cis-2-CAMP.

(±)-cis-2-CAMP.

(±)-cis-H₂-PAT.

(±)-cis-H₂-PAT.

(±)-Citronellal was used to inhibit the development of mechanical nociception induced by carrageenan (CG) and tumor necrosis factor-α (TNF-α).

（±)-Clopidogrel is a thienopyridine adenosine diphosphate (ADP)-receptor antagonist. In addition, this ligand functions as a selective irreversible P2Y12 receptor antagonist. It is known that P2Y12 are ADP receptors located on platelet membranes and

（±)-Clopidogrel is a thienopyridine adenosine diphosphate (ADP)-receptor antagonist. In addition, this ligand functions as a selective irreversible P2Y12 receptor antagonist. It is known that P2Y12 are ADP receptors located on platelet membranes and

（±)-Clopidogrel is a thienopyridine adenosine diphosphate (ADP)-receptor antagonist. In addition, this ligand functions as a selective irreversible P2Y12 receptor antagonist. It is known that P2Y12 are ADP receptors located on platelet membranes and

（±)-Clopidogrel is a thienopyridine adenosine diphosphate (ADP)-receptor antagonist. In addition, this ligand functions as a selective irreversible P2Y12 receptor antagonist. It is known that P2Y12 are ADP receptors located on platelet membranes and